Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of HM10660A versus Pegasys and placebo in healthy men
NL-OMON35906Active, not recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Mar 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of HM10660A in hepatitis B (HBV), hepatitis C virus infection and cancer (3 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Safety and tolerability and Immunogenicity. Started Mar 2011; status: active, not recruiting.
02
Drugs
HM10660A
03
Conditions
hepatitis B (HBV)hepatitis C virus infectioncancer
Beyond the preview
Go deeper on NL-OMON35906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35906.